Parabilis Medicines, Inc. - 8-K Filing

Parabilis Medicines reports Q3 2026 revenue of $2.1 million and a net loss of $44.5 million, supported by $1.1 billion in cash liquidity. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR · November 12, 2026, 12:07 UTC

Tickers: $PBLS

Read the full article at SEC EDGAR

Part of the story EyePoint, Inc. - 8-K Filing (3 articles)

More Regulatory news

Future Vision II Acquisition Corp. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:00 UTC
THUNDER MOUNTAIN GOLD INC - 10-Q Filing SEC EDGAR · November 12, 2026, 15:00 UTC
MiNK Therapeutics, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:49 UTC
SusGlobal Energy Corp. - 10-Q Filing SEC EDGAR · November 12, 2026, 14:42 UTC
Ideal Power Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:25 UTC
DIGI INTERNATIONAL INC - 8-K Filing SEC EDGAR · November 12, 2026, 14:23 UTC
ZeroStack Corp. - 8-K Filing SEC EDGAR · November 12, 2026, 14:22 UTC
Sound Point Meridian Capital, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:22 UTC
Boost Run Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:20 UTC
INTERFACE INC - 8-K Filing SEC EDGAR · November 12, 2026, 14:20 UTC